Strategic Intelligence Report
Generated July 30, 2026
Artificial Intelligence
Cradle
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
1
Chokepoint Score
1 other entity structurally depend on this one
Headquarters
Amsterdam, Netherlands
Website
Employees
90 (2026, approximate)
Founded
2021
Listing
private
Overview
An AI protein engineering software company whose enterprise-grade platform serves six of the top 25 global pharma companies across more than 50 R&D programs. Cradle raised a $73 million Series B to advance its AI protein engineering software, with customers using the platform to speed up early R&D projects by up to 12x and reduce costs by up to 90%; recent case studies include improving a Staphylococcus aureus vaccine's thermostability by 2.5°C in a single optimization round, seven times faster than rational design.
Dependency Map
One hop in each direction — see Strategic Connections below for the full, sourced breakdown of every relationship.
Strategic Connections
Development
- AI Protein Design & Synthetic Biology: Cradle develops an AI protein engineering platform serving six of the top 25 global pharma companies across 50+ R&D programs.
Competition / Other
- Earendil Labs: Cradle competes with Earendil Labs and other AI protein/biologics design companies for pharma partnerships and top computational biology talent.
- EvolutionaryScale: Cradle competes with EvolutionaryScale in AI protein design, though Cradle focuses on an optimization platform for existing biotech R&D teams versus EvolutionaryScale's foundation-model approach.
Strategic Risks
- Optimization-platform approach depends on continued adoption by existing biotech R&D teams rather than owning end-to-end drug programs
- Competitive category with well-funded foundation-model rivals (EvolutionaryScale) and applied-biologics rivals (Earendil Labs)
Future Outlook
- Continued expansion across top-25 pharma customer base beyond current six relationships
- Case-study-driven adoption growth as protein-engineering campaigns demonstrate faster, cheaper results
Sources
- PR Newswire (Jun 2026) — Cradle's AI protein engineering platform serves six of top 25 pharma leaders
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Full Analyst Report — switch to the Executive Summary.